期刊文献+

抗心律失常药物对2-APB诱发大鼠心房异位活动的影响

Inhibition of 2-aminoethoxydiphenyl-borate-induced rat atrial ectopic activity by antiarrhythmic drugs
下载PDF
导出
摘要 目的研究抗心律失常药物对2-APB诱发的大鼠心房异位活动的抑制作用。方法通过连接多通道分析和获取数据的等长张力传感器测量2-APB诱发的异位活动。结果 2-APB剂量依赖性增加左心房的异位活动,浓度分别为1、5、10、20、50μmol·L^(-1)。抗心律失常药物,奎尼丁(10μmol·L^(-1)),利多卡因(10μmol·L^(-1)),维拉帕米(5μmol·L^(-1))抑制2-APB诱发的异位活动。2-APB诱发的异位活动能被无钙液和Na^+/Ca^(2+)交换抑制剂所阻断,如3',4'-dichlorobenzamil hydrochloride(DHC)和Ni^(2+),而不能被非选择性阳离子通道阻断剂Gd^(3+)所阻断。结论 2-APB诱发的心房异位活动能被经典抗心律失常药物所抑制,如奎尼丁,利多卡因,维拉帕米和钠钙交换抑制剂。2-APB可用于筛选那些能够非选择性抑制钠通道,钙通道和钠钙交换体的抗心律失常药物。 Objective To explore the inhibition of 2-APB-induced rat atrial ectopic activity by antiarrhythmic drugs. Methods 2-APB-induced ectopic activity was measured through an isometric force transducer connected to amultichannel acquisition and analysis system. Results 2-APB dose-dependence increased the ectopic activity of left atria at 1,5,10,20,50 μmol·L^(-1). Anti-arrhythmic drugs,quinidine( 10 μmol·L^(-1)),lidocaine( 10 μmol·L-1),verapamil( 5 μmol·L^(-1)) inhibited 2-APB-induced ectopic activity. 2-APB-induced ectopic activity was inhibited by Ca2 +-free bath,Na+/ Ca^(2+)exchanger blockers,3 ',4 '-dichlorobenzamil hydrochloride( DHC) and Ni^(2+),not by non-selective cation channel blocker Gd^(3+). Conclusions 2-APB-induced atrial ectopic activity was inhibited by classic anti-arrhythmic drugs quinidine,lidocaine,verapamil,and Na+/ Ca2 +exchanger blockers. It can be used for testing agents able to affect any of Na^+,Ca^(2+)channel,Na^+/Ca^(2+) exchanger without selectivity.
作者 解岩 张婷婷
出处 《安徽医药》 CAS 2016年第5期832-835,共4页 Anhui Medical and Pharmaceutical Journal
关键词 钠钙交换体抑制剂DHC 抗心律失常药 利多卡因 奎尼丁 维拉帕米 大鼠 WISTAR 2-APB Anti-Arrhythmia Agents Lidocaine Quinidine Verapamil Rats,Wistar 2-Aminoethoxydi pheny borate
  • 相关文献

参考文献6

二级参考文献83

  • 1胡大一,杨进刚.心房颤动的现代观点 (1)我国心房颤动流行概况和危害[J].中国循环杂志,2004,19(5):323-324. 被引量:40
  • 2黄从新.心房颤动的现代观点(2)心房颤动发病机制的现代观念[J].中国循环杂志,2004,19(6):402-405. 被引量:17
  • 3杨宝峰 见:苏定冯 缪朝玉 王永铭主编.抗心律失常中药存在问题的探讨[A].见:苏定冯,缪朝玉, 王永铭主编.药理学进展[C].北京:人民卫生出版社,2001.126~30.
  • 4Camm AJ,Kirchhof P,Lip GY.Guidelines for the management of atrial fibrillation.Eur Heart J,2010,31:2369-2429.
  • 5Wann LS,Curtis AB,January CT.Guidelines focused update:Atrial fibrillation.Circulation,2011,123:104-123.
  • 6Kober L,Trop-Pedersen C,McMurray JJ.Increased mortality after dronedarone therapy for severe heart failure.N Engl J Med,2008,358:2678-2687.
  • 7Connolly S J,Camm A J,Halperin JL.Dronedarone in high-risk permanent atrial fibrillation.N Engl J Med,2011,365:2268-2276.
  • 8Antzelevitch C,Burashnikov A,Sicouri S.Electrophysiologic basis for the antiarrhythmic of ranolazine.Heart Rhythm,2011,8:1281-1290.
  • 9Burashnikov A,Antzelevitch C.New developments in atrial antiarrhymic drug therapy.Nat Rev Cardiol,2010,7:139-148.
  • 10Cheng JWM,Rybak I.Pharmacotherapy options in atrial Fibrillation:Focus on Vernakalant.Clin Med:Therapeutics,2009,1:215-230.

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部